INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

INmune Bio Stock Performance

NASDAQ INMB opened at $8.31 on Thursday. The firm’s 50 day moving average price is $8.14 and its 200-day moving average price is $6.29. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72. The company has a market cap of $220.97 million, a PE ratio of -3.81 and a beta of 1.93.

Analysts Set New Price Targets

Several brokerages have weighed in on INMB. Maxim Group raised their target price on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Rodman & Renshaw began coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price for the company. Scotiabank raised their target price on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Tuesday, February 11th. Finally, RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.